betadex and scutellarein

betadex has been researched along with scutellarein* in 2 studies

Other Studies

2 other study(ies) available for betadex and scutellarein

ArticleYear
Host-guest inclusion system of scutellarein with 2-hydroxypropyl-beta-cyclodextrin: preparation, characterization, and anticancer activity.
    Journal of biomaterials science. Polymer edition, 2014, Volume: 25, Issue:6

    The inclusion complexation behavior of scutellarein (SCUE) with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) has been investigated in both solution and in the solid state. SCUE/HP-β-CD solid system was prepared by suspension method. The formation of SCUE/HP-β-CD complex in aqueous solution was demonstrated by fluorescence spectroscopy, and the Job plot showed a maximum at a molar fraction of 0.5, indicating 1:1 inclusion complexation between SCUE and HP-β-CD. However, SCUE/HP-β-CD inclusion complex was characterized by means of XRD, DSC, (1)H, and two-dimensional NMR. Through the complexation between HP-β-CD and SCUE, the water solubility and antitumor activity of SCUE were obviously increased. This satisfactory water solubility and high antitumor activity of the SCUE/HP-β-CD complex will be potentially useful for its application on human colon cancer chemotherapies.

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents; Apigenin; beta-Cyclodextrins; Cell Line, Tumor; Cell Survival; HCT116 Cells; HT29 Cells; Humans; Magnetic Resonance Spectroscopy; Solubility

2014
Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:11

    This work addressed solubility and membrane permeability problems of Biopharmaceutics Classification System (BCS) Class IV glycoside scutellarin (SG) by developing a nanosuspension of its aglycone scutellarein (S) as a precursor. An S nanosuspension containing poloxamer 188 was prepared using antisolvent precipitation where hydroxypropyl-β-cyclodextrin was utilized as a lyophilizing protectant. Particle size and polydispersity index after redispersion were 342.6 ± 18.2 and 0.32 ± 0.06 nm, respectively. The dissolution rate of the S nanosuspension was superior compared with the physical mixture. No free S, but SG and SG's isomer were detected in plasma following oral delivery of SG or S, S nanosuspension or physical mixture of S. The Cmax values of SG after dosing with the S nanosuspension were 12.0, 8.0, and 4.5-fold higher than the SG, S, or physical mixture, respectively. The Tmax and mean residence time (MRTlast ) of SG after dosing with the S nanosuspension were significantly shorter than S and SG. Treatments with SG, S, or S nanosuspensions reduced the hemorrhage rate in a zebrafish model, but the S nanosuspension exhibited the strongest rescue effect. This study highlights a new strategy to circumvent BCS Class IV flavonoid glycosides using a formulation of their aglycone as a precursor to accelerate oral absorption and improve bioactivity.

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Oral; Animals; Apigenin; beta-Cyclodextrins; Biological Availability; Biotransformation; Cerebral Hemorrhage; Chemistry, Pharmaceutical; Disease Models, Animal; Excipients; Freeze Drying; Glucuronates; Nanostructures; Nanotechnology; Particle Size; Poloxamer; Prodrugs; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Zebrafish

2014